Alnylam COO critical of big pharma, FierceDrugDelivery reports

theflyonthewall.com

After Novartis (NVS) decided to end its RNAi research, Alnylam COO Barry Greene told FierceDrugDelivery that big pharma has "never been able to innovate." Greene attributes the recent sell-off in Alnylam shares to "generally bearish sentiment on Wall Street regarding biotech stocks in particular."

View Comments (0)